Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

Speciality: Hematology

Description:

A warm welcome to all the medical professionals in this critical session on Updates on Standard vs. High-Risk Myeloma Treatment- The Next Part. The landscape of multiple myeloma has been transformed by a deeper understanding of its biological heterogeneity, leading to a crucial distinction in treatment strategies based on risk stratification. While patients with standard-risk disease can achieve durable remissions with conventional therapies, those with high-risk features require more intensive and novel approaches to achieve similar outcomes.

Current risk stratification systems, such as the revised International Staging System (R-ISS), integrate both clinical markers and key cytogenetic abnormalities to accurately identify high-risk patients. These high-risk patients often have features like del(17p), t(4;14), and t(14;16) which are associated with more aggressive disease and a higher chance of early relapse. Therefore, for high-risk myeloma, the treatment paradigm shifts toward more potent, quadruplet regimens that often include a monoclonal antibody, a proteasome inhibitor, an immunomodulatory drug, and a steroid.

Ultimately, the core difference lies not just in the drugs used but in the entire treatment philosophy. For standard-risk patients, the goal is a deep response followed by maintenance therapy, which is often sufficient. For high-risk patients, the goal is to achieve minimal residual disease (MRD) negativity with aggressive induction therapy, often followed by a tandem autologous stem cell transplant and more intensive maintenance regimens. This personalized, risk-adapted approach is essential for bridging the survival gap between the two groups.

See More Webinars @ Hidoc Webinars